ZLDPF Zealand Pharma A/S

Zealand Pharma convenes its Annual General Meeting 2025

Zealand Pharma convenes its Annual General Meeting 2025

Company Announcement – No. 3 / 2025

Zealand Pharma convenes its Annual General Meeting 2025

Notice to convene the Annual General Meeting 2025 of Zealand Pharma A/S (CVR no. 20 04 50 78) (the "Company").

The Board of Directors of the Company hereby convenes the Annual General Meeting of the Company to be held on:

Thursday, March 27, 2025 at 3:00 pm (CET)

The Annual General Meeting will be held as a partly electronic general meeting with the possibility of attending electronically or in person (hybrid meeting).

The Annual General Meeting will be held electronically via the virtual portal hosted by Computershare A/S, and physically at the Company's registered address Sydmarken 11, DK-2860 Søborg.

Please find further information in the accompanying attachment.

Attachment



EN
20/02/2025

Underlying

ZLDPFZealand Pharma A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Zealand Pharma A/S

 PRESS RELEASE
Free
ZLDPF Zealand Pharma ...

Zealand Pharma convenes its Annual General Meeting 2025

Zealand Pharma convenes its Annual General Meeting 2025 Company Announcement – No. 3 / 2025 Zealand Pharma convenes its Annual General Meeting 2025 Notice to convene the Annual General Meeting 2025 of Zealand Pharma A/S (CVR no. 20 04 50 78) (the "Company"). The Board of Directors of the Company hereby convenes the Annual General Meeting of the Company to be held on: Thursday, March 27, 2025 at 3:00 pm (CET) The Annual General Meeting will be held as a partly electronic general meeting with the possibility of attending electronically or in person (hybrid meeting). The Annual General M...

February 20, 2025 1 EN
 PRESS RELEASE
Free
ZLDPF Zealand Pharma ...

Correction: Zealand Pharma Announces Financial Results for the Full Ye...

Correction: Zealand Pharma Announces Financial Results for the Full Year 2024 Company announcement – No. 2 / 2025 Correction includes 2024 Annual Report attached in iXBRL format. Zealand Pharma Announces Financial Results for the Full Year 2024 A transformational year with significant clinical advancement across differentiated obesity pipeline, while building the foundation for accelerated growth in the years to come Positive results with long-acting amylin analog petrelintide in 16-week Phase 1b trial and advancement into large, comprehensive Phase 2b trial in people with overweight or...

February 20, 2025 1 EN
Thomas Vranken
  • Thomas Vranken
ZLDPF Zealand Pharma ...

Zealand Pharma FIRST LOOK: FY24 results underline pipeline progress

Zealand reported its FY24 results, highlighting significant progress in its pipeline. Key developments include positive results for petrelintide, dapiglutide, and survodutide, with several trials advancing to the next phases in 2025. The company reported a YE24 cash position of $ 1.3bn, supporting accelerated momentum in 2025 with important clinical advancements while it aims to secure a partnership for petrelintide. We reiterate our DKK 970 TPP and Buy rating.

ZLDPF ZEALAND PHARMA A/S
02/20/25 February 20, 2025 1 EN
Guy Sips ... (+7)
  • Guy Sips
  • Hilde Van Boxstael
  • Sharad Kumar S.P
  • Thibault Leneeuw
  • Thomas Couvreur
  • Thomas Vranken
  • Wim Lewi
FAGR FAGRON SA
GIMB GIMV NV ... (+9)

Morning Notes : AGN NA, BESI NA, FAGR BB, GIMB BB, KIN BB, NN NA, VGP ...

: AGN NA, BESI NA, FAGR BB, GIMB BB, KIN BB, NN NA, VGP BB, AZE BB, ZEAL DC

FAGR FAGRON SA
GIMB GIMV NV
ZLDPF ZEALAND PHARMA A/S
VGP VGP NV
KIN KINEPOLIS GROUP NV
NN NN GROUP N.V.
BESI BE SEMICONDUCTOR INDUSTRIES N.V.
AZE AZELIS GROUP NV
AGN AEGON N.V.
02/20/25 February 20, 2025 1 EN
 PRESS RELEASE
Free
ZLDPF Zealand Pharma ...

Zealand Pharma Announces Financial Results for the Full Year 2024

Zealand Pharma Announces Financial Results for the Full Year 2024 Company announcement – No. 2 / 2025 Zealand Pharma Announces Financial Results for the Full Year 2024 A transformational year with significant clinical advancement across differentiated obesity pipeline, while building the foundation for accelerated growth in the years to come Positive results with long-acting amylin analog petrelintide in 16-week Phase 1b trial and advancement into large, comprehensive Phase 2b trial in people with overweight or obesity Positive topline results with GLP-1/GLP-2 receptor dual agonist dapi...

February 20, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch